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INTRODUCTION
Strongyloidiasis is a common parasitic infection
estimated to affect more than 70 million people
worldwide. It is endemic in tropical and subtropical
countries including Southeast Asia, Sub-Saharan Africa,
South America and Eastern Europe, with prevalence
rates reported to be as high as 30% [1,2]. Most infected
pat ients  are  asymptomat ic  or  exhibi t  mi ld
gastrointestinal symptoms only. Its association with
nephrotic syndrome is usually in the context of
disseminated infection secondary to the use of
immunosuppressants [3–7]. However, strongyloidiasis
as a cause of nephrotic syndrome has seldom been
reported [8–10].
CASE REPORT
A 77-year-old woman was admitted to Queen Mary
Hospital for worsening bilateral ankle swelling of 1
month’s duration in March 2007. She was born in the
rural area of Xinhui, Guangdong in southern China and
Nephrotic Syndrome Secondary to Strongyloidiasis: A Common
Infection with an Uncommon Presentation
Jasper Fuk-Woo Chan, Bo-Ying Choy, Kar-Neng Lai
Disseminated strongyloidiasis has often been linked with the use of immunosuppressants in patients with
nephrotic syndrome. Nephrotic syndrome secondary to Strongyloides stercoralis infection, however, is a rare
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immigrated to Hong Kong at the age of 12. She did not
smoke or drink and had no known allergy. Her medical
history included hypertension diagnosed 5 years
previously, which was being controlled with nifedipine
SR 20 mg twice daily and indapamide 2.5 mg daily,
and bronchial asthma since childhood. Her only major
asthma attack in recent years was 4 months previously,
which had been stabilized with a 3-week course of high-
dose prednisolone.
On physical examination, she was afebrile, had a
blood pressure of 134/65 mmHg and a heart rate of 82
beats per minute. She had bilateral lower limb pitting
edema up to the mid shin, and purpuric rash over the
buttock and thighs. Her cardiovascular, respiratory,
abdominal and neurologic examinations were otherwise
unremarkable.
Chest radiograph showed clear lung fields with a
normal cardiothoracic ratio. Her electrocardiogram was
in sinus rhythm with no evidence of ischemia.
Laboratory investigations revealed mildly raised serum
creatinine of 146 +mol/L, blood urea of 12.8 mmol/L,
and serum bicarbonate, sodium and potassium of 21,
140 and 3.3 mmol/L, respectively. She had normal
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clotting profile and liver function tests except for
marked hypoalbuminemia of 13 g/L. Her 24-hour
urinary protein excretion was in the nephrotic range of
12.61 g/day. She also had hyperlipidemia with fasting
cholesterol of 8.2 mmol/L (low-density lipoprotein,
6.0 mmol/L; high-density lipoprotein, 0.93 mmol/L)
and triglycerides of 2.7 mmol/L. Her complete blood
picture showed leukocytosis of 10.60 × 109/L with
eosinophilia of 3.50 × 109/L. Her hemoglobin level was
13.3 g/dL and platelet count was 236 × 109/L (Table 1).
Further work-up for her newly diagnosed nephrotic
syndrome was carried out. Doppler ultrasound scan
showed normal-sized kidneys with no renal vein
thrombosis. Her fasting blood glucose was 4.9 mmol/L.
Immunologic tests were inconclusive, with the only
abnormalities being a raised antinuclear antibody titer
of 1/720, C-reactive protein of 0.78 mg/dL, and
immunoglobulin A level of 634 mg/dL. Her
antineutrophil cytoplasmic antibody was negative and
her C3 and C4 levels were normal. Malignancy
Table 1. Comparison of the patient’s laboratory findings at presentation and follow-up
Investigation At presentation At follow-up
(03/2007) (05/2007)
Complete blood picture
White cell count 10.60 × 109/L 6.40 × 109/L
Neutrophil 4.00 × 109/L 3.30 × 109/L
Lymphocyte 2.30 × 109/L 2.30 × 109/L
Eosinophil 3.50 × 109/L 0.30 × 109/L
Hemoglobin 13.3 g/dL 11.4 g/dL
Platelet 236 × 109/L 276 × 109/L
Renal function tests
Sodium 140 mmol/L 146 mmol/L
Potassium 3.3 mmol/L 3.6 mmol/L
Urea 12.8 mmol/L 4.9 mmol/L
Creatinine 146 +mol/L 83 +mol/L
Liver function tests
Total bilirubin 3 +mol/L 9 +mol/L
Alkaline phosphatase 163 U/L 107 U/L
Alanine aminotransferase 8 U/L 5 U/L
Aspartate aminotransferase 18 U/L 20 U/L
Albumin 13 g/L 40 g/L
Immunology
Antinuclear antibody titer 1/720 1/720
Antineutrophil cytoplasmic Ab Negative Negative
Immunoglobulin G 1,190 mg/dL 897 mg/dL
Immunoglobulin A 634 mg/dL 296 mg/dL
Immunoglobulin M 134 mg/dL 73 mg/dL
C-reactive protein 0.78 mg/dL < 0.35 mg/dL
C3/C4 89/34 mg/dL
Tumor markers
Alpha-fetoprotein 2 ng/mL
Carcinoembryonic antigen 2.9 ng/mL 2.2 ng/mL
CA15.3 37 U/mL 20 U/mL
Microbiology
Hepatitis B surface antigen Negative
Hepatitis B surface antibody Positive
Urine culture No growth No growth
Stool ova and cyst S. stercoralis rhabditiform larvae No ova or cyst detected
24-hr urinary protein excretion 12.61 g/d 0.15 g/d
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screening was unremarkable apart from a mildly
elevated CA15.3 level of 37 U/mL. A mammogram and
positron emission tomography scan were thus
performed, with neither showing any evidence of an
underlying malignancy. Urine for microscopy was
unremarkable and culture yielded no growth. She was
immune to hepatitis B with positive hepatitis B surface
antibody. Investigation for the eosinophilia, however,
showed that the patient suffered from Strongyloides
infestation with S. stercoralis larvae being found in
stool.
As the patient was not keen for renal biopsy and
in view of previous sporadic reports of remission of
nephrotic syndrome after anthelmintics in patients
suffering from strongyloidiasis [6–8,10], she was
treated with a 10-day course of albendazole. After
completion of the course of albendazole, the patient
gradually showed symptomatic improvement with
resolution of lower limb edema and purpuric rash
over the following 2–3 months. Subsequent 24-hour
urinary protein measurements taken 2 months after
treatment confirmed significant decrease in proteinuria
to 0.15 g/day (Figure). Serum albumin level had risen
to 40 g/L and serum creatinine level had decreased to
83 +mol/L (Table 1). Eosinophil count, C-reactive
protein and CA15.3 levels were also normalized.
Repeated stool samples were negative for S. stercoralis.
She remained well and stable at follow-up 5 months
after presentation.
DISCUSSION
Nephrotic syndrome secondary to parasitic infections
has previously been associated with malaria,
schistosomiasis and filariasis. However, cases due to
strongyloidiasis have rarely been reported. We describe
a patient who developed nephrotic syndrome with S.
stercoralis larvae detected in stool after recent use of
steroid for an asthma attack. She subsequently achieved
complete remission clinically and biochemically after
treatment with albendazole. The absence of other
identifiable causes, the presence of steroid as a
precipitating factor, the time course of development and
resolution strongly suggested that this case was a rare
manifestation of strongyloidiasis presenting as
nephrotic syndrome.
A distinctive characteristic of S. stercoralis is its
ability to survive and replicate inside the human host
while producing minimal symptoms for decades after
infection. In symptomatic patients, the most common
findings are fever and gastrointestinal upset [3,11]. In
disseminated cases, the nematode can virtually affect
every organ with the most prominent manifestations
being gastrointestinal and pulmonary [3,12].
Dermatologic lesions are variable, with the most
characteristic being larva currens, a serpiginous
urticarial eruption, in chronic strongyloidiasis; and
widespread petechiae and purpura in the disseminated
form as observed in our patient [13,14]. Renal failure
secondary to disseminated infection and superimposed
bacterial infections are occasionally encountered,
whereas nephrotic syndrome are uncommonly seen.
An extensive review of the medical literature
identified only three other sporadic case reports of
strongyloidiasis-induced nephrotic syndrome (Table 2)
[8–10]. In 1998, Wong et al reported a case of a middle-
aged woman who presented with nephrotic syndrome
that was resistant to steroid and cyclophosphamide [8].
Subsequent ly  she  deve loped  d i ssemina ted
strongyloidiasis and was treated with thiabendazole.
Interestingly, after treatment with the anthelmintic, the
patient achieved clinical remission and remained free
of recurrence.
Yee et al reported a similar case in 1999 [9]. Hsieh
et al described a patient who suffered from
strongyloidiasis-induced nephrotic syndrome without
preceding immunosuppressive therapy in 2006 [10]. As
in our case, the patients described in these cases all
achieved clinical and biochemical remission after the
underlying Strongyloides infection was treated.
A number of interesting observations can be made
from further analysis of this series of case reports. First,
almost all of the patients described have had a history
of steroid use. As in our patient, the major risk factor
for severe strongyloidiasis is the use of steroid and
immunosuppressive drugs [15,16]. Other risk factorsFigure. Serial trend in serum albumin and proteinuria levels.
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include advanced age, chronic illnesses, malignancies
(especially hematologic), and human T cell leukemia
virus type 1 infection (HTLV-1) [17].
Another common finding among the reported cases
is the presence of peripheral eosinophilia. This is of
clinical interest in two ways. It prompts the physician
to make an early diagnosis, especially among nephrotic
patients from an endemic area and in whom risk factors
are present. Second, it has been advocated, along with
enzyme-linked immunosorbent assay (ELISA), as a
useful laboratory marker of treatment success for
Strongyloides infection [18]. ELISA has emerged as a
reliable serodiagnostic tool for strongyloidiasis, with a
high sensitivity of 94–97% and specificity of 95% [19,
20].
Besides peripheral eosinophilia, renal biopsy
findings are also similar among the reported cases.
Interestingly, all of them yielded minimal change
disease as the underlying renal histopathology, with
two of them showing positive immunofluorescence
for C3. It is postulated that T lymphocytes play a
crucial role in the development of strongyloidiasis-
associated minimal change disease. While the
pathogenesis of minimal change disease has long been
linked with the action of abnormal T cell response
[21–23], the association between hyperinfection with
S. stercoralis and HTLV-1 has also been well
recognized [17,24]. Further studies are necessary to
confirm this hypothesis.
In terms of treatment response, the reported cases
have also demonstrated an important point. Treatment
with steroid caused clinical exacerbation whereas
remissions were only possible after the institution of
anthelmintics including albendazole, thiabendazole and
ivermectin. Clinical improvement was evident on an
average of 1–2 months after the use of anthelmintics.
Based on these findings and the treatment success in
our patient, we advocate that in cases of nephrotic
syndrome where renal biopsy is contraindicated or
when it is refused by the patient, empirical steroid
therapy should only be instituted with caution after
underlying parasitic infections have been excluded in
order to prevent the possibly disastrous outcome of
disseminated disease.
In conclusion, we have reported a case of nephrotic
syndrome that was likely to have been caused by S.
stercoralis infection. Previous case reports have
identified minimal change nephropathy as the common
underlying histopathology. We advocate establishing
diagnosis early on by adopting a high index of clinical
suspicion, especially among those patients who come
from endemic areas, who have identifiable precipitating
factors and peripheral eosinophilia. As we become more
aware of the possible causal relationship between the
two entities, more cases are likely to be identified in
the future. This will in turn help us to gain more
knowledge on the pathogenesis, histopathologic
characteristics and treatment approaches of this
distinctive clinical syndrome. The fatal outcome of
disseminated strongyloidiasis secondary to injudicious
use of immunosuppressive therapy can thus be avoided
and complete remission may then be achieved with
appropriate anthelmintics.
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